cGAS-STING and immune responses for pediatric neuroblastoma
Official title: cGAS-STING and therapeutic immune responses in neuroblastoma
Funded at Children's Hosp of Philadelphia · NIH-11382165 · Data updated 2026-11-12
A training-focused program to help a pediatric oncologist develop new immune-based approaches to treat neuroblastoma in children.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $211,259 |
| NIH project number | 5K08CA266914-05 |
| Project ID | NIH-11382165 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pediatric patients with neuroblastoma or related tumor biology may benefit from future translational advances arising from this work.
✕Less likely to help
Direct patient benefits are unlikely during training years, but groundwork could enable future trials for pediatric neuroblastoma.
What this research studies
This grant supports a five-year training program for an aspiring pediatric oncologist to advance immunotherapy for pediatric solid tumors by studying inflammatory sensing pathways. The mentee will gain skills in transcriptional regulation, immunocompetent mouse models of neuroblastoma, and analysis of the tumor immune microenvironment. The project centers on the cGAS-STING pathway and how its regulation could improve immune targeting of neuroblastoma mesenchymal states. Mentors and a diverse committee guide the candidate, with resources from CHOP, UPenn, and the Wistar Institute to accelerate career development.
Why it matters
Potential benefit: If successful, the research could lead to new immunotherapy strategies for children with neuroblastoma.
How similar studies have gone: Prior work in immunotherapy and inflammatory pathways has shown promise in cancer models, suggesting potential translational impact with further development.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Wolpaw, Adam J — Children's Hosp of Philadelphia
- Study coordinator: Wolpaw, Adam J
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.